Treatment of heparin-induced thrombocytopenia in cardiovascular patients.

Autor: Matthai WH Jr; Penn Presbyterian Medical Center, WS 392, Philadelphia, PA 19104, USA. william.matthai@uphs.upenn.edu
Jazyk: angličtina
Zdroj: Expert opinion on pharmacotherapy [Expert Opin Pharmacother] 2006 Feb; Vol. 7 (3), pp. 267-76.
DOI: 10.1517/14656566.7.3.267
Abstrakt: Heparin-induced thrombocytopenia (HIT) is an antibody-mediated syndrome associated with heparin exposure, a falling platelet count and a high risk of thrombosis. Cardiovascular patients are at increased risk of HIT due to wide use of heparin in this population. Should HIT be suspected, heparin must be avoided in most situations, and anticoagulation with an alternative anticoagulant should be instituted. Preferred agents include the direct thrombin inhibitors argatroban and lepirudin, whilst bivalirudin or desirudin (other direct thrombin inhibitors) can be used in some situations. The indirect thrombin inhibitors, danaparoid and fondaparinux, can also be considered at times. These agents and their use in cardiac patients, including patients with acute coronary syndrome, percutaneous coronary interventions, acute ST elevation myocardial infarction or cardiac surgery, will be reviewed.
Databáze: MEDLINE